Literature DB >> 18317454

No impact of NOD2/CARD15 on outcome after SCT.

D Sairafi1, M Uzunel, M Remberger, O Ringdén, J Mattsson.   

Abstract

Recent studies have pointed towards an association between certain single nucleotide polymorphisms (SNPs) in the NOD2/CARD15 gene, and negative outcome of Allo-SCT. In this study, 198 patients and their corresponding donors were analyzed retrospectively for the occurrence of NOD2/CARD15 mutations to evaluate the impact on clinical results after Allo-SCT. In all, 7.6% of the patients and 11% of the donors were heterozygous for one of three SNPs 8, 12 or 13. Contrary to earlier findings, we found no significant impact on incidence of acute GVHD or TRM following Allo-SCT. These differences in results could be due to a lower mutation frequency in the studied population and/or a lower overall incidence of severe GVHD. On the basis of these findings we conclude that a consideration to NOD2/CARD15 mutation status is not pertinent when selecting a donor for Allo-SCT at our centre.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317454     DOI: 10.1038/bmt.2008.9

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation.

Authors:  Yume Nguyen; Abed Al-Lehibi; Elizabeth Gorbe; Ellen Li; Michael Haagenson; Tao Wang; Stephen Spellman; Stephanie J Lee; Nicholas O Davidson
Journal:  Blood       Date:  2010-02-22       Impact factor: 22.113

2.  Polymorphisms in innate immunity genes and risk of childhood leukemia.

Authors:  Sohee Han; Qing Lan; Ae Kyung Park; Kyoung-Mu Lee; Sue K Park; Hyo Seop Ahn; Hee Young Shin; Hyoung Jin Kang; Hong Hoe Koo; Jong Jin Seo; Ji Eun Choi; Yoon-Ok Ahn; Stephen J Chanock; Ho Kim; Nathaniel Rothman; Daehee Kang
Journal:  Hum Immunol       Date:  2010-05-16       Impact factor: 2.850

Review 3.  Danger signals activating innate immunity in graft-versus-host disease.

Authors:  Robert Zeiser; Olaf Penack; Ernst Holler; Marco Idzko
Journal:  J Mol Med (Berl)       Date:  2011-05-15       Impact factor: 4.599

Review 4.  Bacterial infections, alloimmunity, and transplantation tolerance.

Authors:  Emily B Ahmed; Melvin Daniels; Maria-Luisa Alegre; Anita S Chong
Journal:  Transplant Rev (Orlando)       Date:  2011-01       Impact factor: 3.943

5.  Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.

Authors:  Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

Review 6.  Advances in predicting acute GVHD.

Authors:  Andrew C Harris; James L M Ferrara; John E Levine
Journal:  Br J Haematol       Date:  2012-12-04       Impact factor: 6.998

Review 7.  Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses.

Authors:  Yoshinobu Maeda
Journal:  Int J Hematol       Date:  2013-08-28       Impact factor: 2.490

8.  The role of bacteria and pattern recognition receptors in GVHD.

Authors:  E Holler; K Landfried; J Meier; M Hausmann; G Rogler
Journal:  Int J Inflam       Date:  2010-10-31

9.  Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHD.

Authors:  Ok S Shin; Jason B Harris
Journal:  Korean J Hematol       Date:  2011-06-21

10.  NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome.

Authors:  Neema P Mayor; Bronwen E Shaw; J Alejandro Madrigal; Steven G E Marsh
Journal:  Bone Marrow Res       Date:  2012-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.